For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Wave Life Sciences Ltd’s stock clocked out at $6.05, up 1.85% from its previous closing price of $5.94. In other words, the price has increased by $1.85 from its previous closing price. On the day, 1.15 million shares were traded.
Ratios:
To gain a deeper understanding of WVE’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.95 and its Current Ratio is at 2.95. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on April 29, 2025, initiated with a Overweight rating and assigned the stock a target price of $10.
On April 08, 2025, Wedbush started tracking the stock assigning a Outperform rating and target price of $18.
On February 25, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $26.Jefferies initiated its Buy rating on February 25, 2025, with a $26 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 20 ’25 when HENRY CHRISTIAN O sold 10,500 shares for $9.77 per share. The transaction valued at 102,574 led to the insider holds 16,115 shares of the business.
Christian Henry bought 10,500 shares of WVE for $102,579 on Mar 20 ’25. On Mar 07 ’25, another insider, BOLNO PAUL, who serves as the President and CEO of the company, sold 169,025 shares for $9.57 each. As a result, the insider received 1,617,569 and left with 338,351 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 8.89 while its Price-to-Book (P/B) ratio in mrq is 5.43.
Stock Price History:
Over the past 52 weeks, WVE has reached a high of $16.74, while it has fallen to a 52-week low of $4.25. The 50-Day Moving Average of the stock is -14.73%, while the 200-Day Moving Average is calculated to be -39.13%.
Shares Statistics:
A total of 154.09M shares are outstanding, with a floating share count of 123.09M. Insiders hold about 20.14% of the company’s shares, while institutions hold 81.47% stake in the company.
Earnings Estimates
The firm’s stock currently is rated by 9.0 analysts. The consensus estimate for the next quarter is -$0.26, with high estimates of -$0.16 and low estimates of -$0.31.
Analysts are recommending an EPS of between -$0.77 and -$1.13 for the fiscal current year, implying an average EPS of -$1.0. EPS for the following year is -$1.02, with 9.0 analysts recommending between -$0.67 and -$1.26.
Revenue Estimates
In the current quarter, 10 analysts expect revenue to total $14.07M. It ranges from a high estimate of $36.99M to a low estimate of $5M. As of the current estimate, Wave Life Sciences Ltd’s year-ago sales were $19.69MFor the next quarter, 10 analysts are estimating revenue of $14.59M. There is a high estimate of $28.99M for the next quarter, whereas the lowest estimate is $5M.
A total of 10 analysts have provided revenue estimates for WVE’s current fiscal year. The highest revenue estimate was $94.2M, while the lowest revenue estimate was $38.17M, resulting in an average revenue estimate of $62.5M. In the same quarter a year ago, actual revenue was $108.3M
